India’s COVID-19 Surge Forced Another Abrupt Stop Of US FDA In-Person Inspections
Executive Summary
Agency inspectors worked in the country for about a month before the coronavirus infection surge forced another halt.
You may also be interested in...
Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says
Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.
Breakthrough COVID-19 Cases Raise Concern Over B.1.617 Variant
As the B.1.617 variant of SARS-CoV-2 spreads to countries including the UK and US after having caused havoc in India, vaccine effectiveness against this variant is under the lens with breakthrough cases reported post full vaccination. Meanwhile, CEPI’s offer to help in testing against variants has potential to harmonize assessment of COVID-19 vaccines performance.
US FDA Cautions Against Blaming CRLs On Inspection Delays
Agency revises pandemic inspection guidance to explain CRL ‘non-deficiency’ inspection comments and update industry on remote interactive evaluations and post-COVID-19 inspection priorities.